FIGURE 6.

LARGE2 expression is diminished during prostate cancer progression. A, microdissected samples of prostate tumor and benign tissue cDNA were obtained and analyzed via qRT-PCR. All samples were normalized to a random, benign control. Carcinoma samples show a markedly reduced level of LARGE2 expression when compared with benign epithelium (benign = 3.999 ± 1.036 a.u., tumor = 1.271 ± 0.3105 a.u., p = 0.0079). B, microdissected samples were all normalized to the patient-matched benign sample with the normalized value of the benign, 1.0, marked by the dashed line. Both Gleason grade 3 and Gleason grade 4 samples show a significant decrease in expression levels (p = 0.0105 and p = 0.0020) when compared with benign. C, analysis of the tissue cDNA array normalized to benign samples. There is a significant decrease of LARGE2 (p = 0.0112) when stage II (disease is completely confined to the prostate) is compared with stage III (extension beyond prostatic capsule or seminal vesicle involvement).